Saleh Yehia, Al-Abcha Abdullah, Abdelkarim Ola, Abdelnabi Mahmoud, Almaghraby Abdallah, Kleiman Neal S
Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, 6550 Fannin St, Smith Tower 18-209, Houston, TX, 77030, USA.
Department of Cardiology, Alexandria University, Alexandria, Egypt.
Am J Cardiovasc Drugs. 2022 May;22(3):231-238. doi: 10.1007/s40256-021-00509-2. Epub 2021 Nov 5.
Left ventricular thrombi form due to the presence of Virchow's triad in patients with left ventricular systolic dysfunction. This complication increases the incidence of systemic embolization, hence anticoagulation is recommended to decrease this risk. Up to the present time, vitamin K antagonists are recommended by all societal guidelines for patients with left ventricular thrombi. Recently, several studies have investigated the role of different anticoagulants and yielded promising outcomes. This opinion article focuses on the evidence supporting vitamin K antagonists and direct oral anticoagulants in patients with left ventricular thrombi.
左心室血栓形成是由于左心室收缩功能障碍患者存在Virchow三联征。这种并发症会增加全身栓塞的发生率,因此建议进行抗凝治疗以降低这种风险。到目前为止,所有社会指南都推荐维生素K拮抗剂用于左心室血栓患者。最近,几项研究调查了不同抗凝剂的作用并取得了有前景的结果。这篇观点文章重点关注支持维生素K拮抗剂和直接口服抗凝剂用于左心室血栓患者的证据。